You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA218
  • Published:  23 March 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee
  • Update information

6 Recommendations for further research

6.1

The Committee recommends that a study estimating utility values using directly observed health-related quality-of-life values (such as EQ-5D scores) in patients with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia is conducted.


Next page 7 Appraisal Committee members and NICE project team Previous page 5 Implementation
Back to top